Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 432K | 137K | 1M | 10M | 10M |
| Gross Profit | 331K | 6K | 49K | 6M | 5M |
| Operating Income | -43.5B | -15M | -4M | -3M | -5M |
| EBITDA | -39M | -17M | -6M | -2M | -5M |
| Net Income | -41.5B | 9M | -18M | -3M | -5M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.382
-1.55% today
1Y Change
-60.89%
Window
Jun 23, 2025 → Jun 8, 2026
Coverage: 241 bars · Jun 23, 2025 → Jun 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Scienture Holdings, Inc. (SCNX) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $0.38 and down 60.9% across the available one-year price window (Jun 23, 2025 → Jun 8, 2026). Baseline metrics include revenue growth of +215.9%, EPS growth of -200.4%, a dividend yield of 0.0%. What stands out right now is revenue +215.9%, EPS -200.4%, free cash flow -93633.0% with operating margin -10079976.7% and ROIC -53.4%. Valuation already assumes a fairly strong business story at price/sales 14.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SCNX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCNX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SCNX Max Drawdown
-90.73%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SCNX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$9.9M
-3.5% YoY
FY Net Income
-$5.3M
-53.1% YoY
Free Cash Flow
-$2.6M
-65.5% YoY
Revenue Growth
+215.9%
EPS Growth
-200.4%
Gross Margin
73.2%
Net Margin
-9618025.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 432K | 137K | 1M | 10M | 10M |
| Gross Profit | 331K | 6K | 49K | 6M | 5M |
| Operating Income | -43.5B | -15M | -4M | -3M | -5M |
| EBITDA | -39M | -17M | -6M | -2M | -5M |
| Net Income | -41.5B | 9M | -18M | -3M | -5M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6.7B | 308K | 314 | 1M | 3M |
| Total Assets | 84.2B | 105M | 13M | 4M | 6M |
| Total Liabilities | 14.1B | 26M | 12M | 3M | 2M |
| Shareholder Equity | 70.1B | 79M | 542K | 763K | 4M |
| Total Debt | 24M | 4M | 7M | 2M | 1M |
| Net Debt | -6.6B | 3M | 7M | 489K | -2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
-64.0% YoY
Capital Expenditures
23K
Free Cash Flow
3M
-65.5% YoY
Key ratios
Gross Margin
73.2%
Operating Margin
-10079976.7%
Net Margin
-9618025.6%
ROE
-236.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.